Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Article Allergy

Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon

Lydia J. Finney et al.

Summary: Inhaled corticosteroids (ICS) treatment in COPD patients reduces the expression of ACE2, the entry receptor for SARS-CoV-2, potentially contributing to a reduced risk of COVID-19 infection in these patients.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Virology

The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells

Shutoku Matsuyama et al.

Summary: The study found that the inhaled corticosteroid ciclesonide can inhibit the replication of coronaviruses, including SARS-CoV-2, with potential use in treating COVID-19. Ciclesonide also successfully suppressed the replication of 15 resistant mutants, making it a promising broad-spectrum antiviral drug.

JOURNAL OF VIROLOGY (2021)

添加到收藏夹

Editorial Material Critical Care Medicine

SARS-CoV-2-triggered Immune Reaction: For COVID-19, Nothing Is as Old as Yesterday's Knowledge

Tobias Welte

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Christopher C. Butler et al.

Summary: The use of azithromycin does not show significant benefits in reducing recovery time or risk of hospitalization for people with suspected COVID-19 in the community. This finding underscores the importance of prudent antibiotic use during the pandemic, as increased antibiotic use can lead to antimicrobial resistance.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Anthony C. Gordon et al.

Summary: Interleukin-6 receptor antagonists tocilizumab and sarilumab were found to improve outcomes, including survival, in critically ill patients with Covid-19 receiving organ support in ICUs according to an ongoing international trial. The efficacy of these treatments has been confirmed, with patients benefiting from the therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

Sanjay Ramakrishnan et al.

Summary: The study found that early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and accelerated recovery time in patients with early COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study

Paul Aveyard et al.

Summary: The study found that patients with certain respiratory diseases had a higher risk of hospitalization and death from COVID-19, while the risk of severe COVID-19 in asthma patients was relatively small. The use of inhaled steroids may be associated with a slightly increased risk of severe COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal